Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differential perforin sensitivity drives lineage-dependent resistance to CAR T-cell killing in blood cancer cell lines.

Blood advances·2026
Same author

Persistent and pathogen-specific infection risk during long-term survivorship after CD19 CAR-T: An Australian multi-centre cohort study.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same author

Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-Up.

Advances in therapy·2026
Same author

A Critical Review of Clinical Factors and Tools for Predicting Chimeric Antigen Receptor T-Cell Toxicities.

Transplantation and cellular therapy·2026
Same author

Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma.

Blood advances·2026
Same author

Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial.

The Lancet. Haematology·2026
Same journal

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

Blood·2026
Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026
Same journal

ELISA-negative HIT: antibody recognition and relevance.

Blood·2026
Same journal

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026
Same journal

A bone to pick with ferric carboxymaltose.

Blood·2026
Same journal

A step toward streamlining HIT diagnosis.

Blood·2026
See all related articles

Related Experiment Video

Updated: Apr 27, 2026

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

10.3K

A new prognostic score for CLL.

Constantine S Tam1, John F Seymour1

  • 1PETER MACCALLUM CANCER CENTRE; UNIVERSITY OF MELBOURNE.

Blood
|July 5, 2014
PubMed
Summary
This summary is machine-generated.

Pflug et al introduce a new prognostic score for chronic lymphocytic leukemia (CLL) developed by the German CLL Study Group. This score aids in predicting patient outcomes and guiding treatment strategies for CLL.

More Related Videos

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

13.2K
Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

879

Related Experiment Videos

Last Updated: Apr 27, 2026

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

10.3K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

13.2K
Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

879

Area of Science:

  • Hematology
  • Oncology
  • Clinical Research

Background:

  • Chronic lymphocytic leukemia (CLL) is a common B-cell malignancy.
  • Accurate prognostic tools are crucial for optimizing CLL patient management.
  • The German Chronic Lymphocytic Leukemia Study Group (GCLLSG) has a history of contributing to CLL research.

Purpose of the Study:

  • To present and validate a novel prognostic score for chronic lymphocytic leukemia.
  • To provide clinicians with an improved tool for patient risk stratification.
  • To enhance the understanding of prognostic factors in CLL.

Main Methods:

  • Development and validation of a new prognostic scoring system.
  • Utilized data from patients within the German Chronic Lymphocytic Leukemia Study Group.
  • Analysis of clinical and biological parameters relevant to CLL prognosis.

Main Results:

  • The study describes a new prognostic score for CLL.
  • The score incorporates key factors to predict disease progression and survival.
  • Validation of the score demonstrates its clinical utility.

Conclusions:

  • The newly developed prognostic score offers a valuable tool for managing CLL patients.
  • This score can aid in personalized treatment decisions.
  • Further research may refine the score's application in diverse CLL populations.